ARD-501 / Aardvark Therap - LARVOL DELTA

A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder (clinicaltrials.gov) - P2 | N=5 | Completed | Sponsor: Aardvark Therapeutics, Inc. | Active, not recruiting ➔ Completed | N=12 ➔ 5 | Trial completion date: Jun 2025 ➔ Jan 2025

Enrollment change • Trial completion • Trial completion date • Autism Spectrum Disorder • Genetic Disorders

A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder (clinicaltrials.gov) - P2 | N=12 | Active, not recruiting | Sponsor: Aardvark Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Autism Spectrum Disorder • Genetic Disorders

A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: Aardvark Therapeutics, Inc. | Trial completion date: Jul 2024 ➔ Jun 2025 | Initiation date: Jan 2024 ➔ Aug 2024 | Trial primary completion date: Apr 2024 ➔ Dec 2024

Trial completion date • Trial initiation date • Trial primary completion date • Autism Spectrum Disorder • Genetic Disorders

A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: Aardvark Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Autism Spectrum Disorder • Genetic Disorders